Blood test study to predict immunotherapy success in liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (liver cancer).
- You agree to have all your tests, treatments, and follow-up done at our center.
- You do not have any immune system disorders (like autoimmune diseases).
- You do not have HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Hear when a new Liver Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.